Photo: open.spotify.com
Apr 21, 2026, 14:44
Continuing the Conversation on Factor VIII – EAHAD
European Association for Haemophilia and Allied Disorders (EAHAD), shared a post on LinkedIn:
”Continuing the conversation on Factor VIII!
As innovations such as emicizumab, rebalancing agents, and gene therapy continue to transform care, what is the place of FVIII today, and where is it heading next?”
Stay updated with Hemostasis Today.
-
Apr 21, 2026, 15:09William Aird: White Blood Cells Unpacked
-
Apr 21, 2026, 15:06Can Lived Experiences Shape Future Advances in Haemophilia Care? – Novo Nordisk
-
Apr 21, 2026, 15:04Abdelrahman Omran: Blood Transfusion as a High-Risk Intervention in Acute Care
-
Apr 21, 2026, 14:58Giuseppe Lippi: A New Step in Robotic Phlebotomy
-
Apr 21, 2026, 14:53Leonardo Roever: Integrated Clinical Guidelines for Managing Brain-Heart Multimorbidity
-
Apr 21, 2026, 14:50WFH Volunteer Awards
-
Apr 21, 2026, 14:36Chokri Ben Lamine: 50 Pearls Credits on How is Breakthrough Thrombosis in Patients with Cancer Being Treated
-
Apr 21, 2026, 14:26Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” – Key Insights from WFH 2026
-
Apr 21, 2026, 13:50ITP Care in Your Language – ITP Support Association